The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.
About this Study
Randomized, quadruple blind parallel design
45 participants estimated to be completed June 2020
- Ages Eligible for Study: 18 Years and older (adult, Older Adult)
- Sexes Eligible for Study: All
- Accepts Healthy Volunteers: No
- The presence of orthostatic hypotension (fall in systolic BP greater than or equal to 30 mm Hg) is required for this study;
- Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic etiology.
How to participate
In order to participate in a study, you must personally contact the study coordinator of any of the participating institutions by phone or by e-mail. Please use the information below to inquire about participation